HYDROMORPHONE

- Everything we could find out about it

Home ] [ Controlled Substances ] [ Opioids ]

Created Aug 2019 | Updated Oct 2020

HYDROMORPHONE

  • [DILAUDID]
  • [DIHYDROMORPHINONE]
  • [EXALGO]
  • [PALLADONE]

Hydromorph Contin

DEA CODE 9150: Schedule 2 Narcotic

Hydromorphone

Hydromorphone

Hydromorphone (also known as dihydromorphinone and the brand name Dilaudid among others) is a more potent opioid analgesic than morphine and is used for moderate to severe pain. It can be administered by injection, by infusion, by mouth, and rectally. Oral bioavailability is low. The kidney excretes hydromorphone and its metabolites. Some metabolites may have greater analgesic activity than hydromorphone itself but are unlikely to contribute to the pharmacological activity of hydromorphone. With the exception of pruritus, sedation and nausea and vomiting, which may occur less after hydromorphone than after morphine, the side-effects of these drugs are similar. Hydromorphone interacts predominantly with the opioid mu-receptors. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. It also binds with kappa and delta receptors which are thought to mediate spinal analgesia, miosis and sedation.

Dilaudid was the brand name of the first drug containing hydromorphone. It was introduced in 1926 and remained the only brand name drug that contained hydromorphone for more than 50 years. Today, people commonly refer to generic versions of hydromorphone as Dilaudid. These medications come in pill, injection and liquid forms. Hydromorphone is a prescription painkiller that belongs to a class of drugs called opioids. It's two to eight times stronger than morphine. For decades, Dilaudid was a popular alternative to morphine for the treatment of pain. Other brand names for drugs containing hydromorphone include Exalgo, introduced in 1984, and Palladone, introduced in 2004. Both drugs came in extended-release pill formulations. Palladone was withdrawn from the market in 2005 because it caused potentially fatal side effects when mixed with alcohol.

Hydromorphone is a potent schedule II opioid analgesic drug. Hydromorphone abuse has been a continuing problem in the United States. It is marketed as injectable ampoules, multiple dose vials, tablets and suppositories. Hydromorphone is indicated for relief of moderate-to-severe pain. Hydromorphone is marketed under brand names, Dilaudid and Exalgo. It is also marketed in generic forms. Street Names: Dust, Juice, Smack, D, Footballs.

Hydromorphone drug usage

205th most prescribed medicine in the United States for 2017

Hydromorphone belongs to the group of medicines called narcotic analgesics (pain medicines). It acts on the central nervous system (CNS) to relieve pain. When a narcotic medicine is used for a long time, it may become habit-forming, causing mental or physical dependence. However, people who have continuing pain should not let the fear of dependence keep them from using narcotics to relieve their pain. Mental dependence (addiction) is not likely to occur when narcotics are used for this purpose. Physical dependence may lead to withdrawal side effects if treatment is stopped suddenly. However, severe withdrawal side effects can usually be prevented by gradually reducing the dose over a period of time before treatment is stopped completely.

This medicine is available only under a restricted distribution program called the Opioid Analgesic REMS (Risk Evaluation and Mitigation Strategy) program.

Pediatric:
Appropriate studies have not been performed on the relationship of age to the effects of hydromorphone injection in the pediatric population.

Safety and efficacy have not been established.

Geriatric:
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of hydromorphone injection in the elderly. However, elderly patients are more likely to have age-related lung, kidney, liver, or heart problems, which may require caution and an adjustment in the dose for patients receiving hydromorphone injection in order to avoid serious side effects.

Other Interactions:

  • Ethanol

Other Medical Problems:
Make sure you tell your doctor if you have any other medical problems, especially:

  • Addison disease (adrenal gland problem)
  • Alcohol abuse, acute
  • Breathing or lung problems, severe (eg, asthma, apnea, low oxygen levels)
  • Chronic obstructive pulmonary disease (COPD)
  • Cor pulmonale (serious heart condition)
  • Depression, history of
  • Drug dependence, especially narcotic abuse or dependence, or history of
  • Gallbladder disease or gallstones
  • Head injury, history of
  • Hypothyroidism (an underactive thyroid)
  • Kyphoscoliosis (curvature of the spine with breathing problems)
  • Mental health problems, history of
  • Problems with passing urine
  • Prostatic hypertrophy (enlarged prostate, BPH) - Use with caution. May increase risk for more serious side effects
  • Allergy to sulfites
  • Stomach or bowel blockage (eg, paralytic ileus) - Should not be used in patients with these conditions
  • Hypotension (low blood pressure)
  • Pancreatitis (inflammation of the pancreas)
  • Seizures, history of - Use with caution. May make these conditions worse
  • Kidney disease
  • Liver disease - Use with caution. The effects may be increased because of slower removal of the medicine from the body
  • Patients who are not opioid-tolerant - Dilaudid-HP should not be given in these patients

Dilaudid is one of the more powerful synthetic narcotics in the opioid class of drugs and an addiction to Dilaudid can rapidly develop through continued use. People regularly taking Dilaudid build up a tolerance to the drug, requiring larger and more frequent doses to get the desired effects. Users can develop a tolerance to Dilaudid within two or three weeks. Once a tolerance takes hold, users taking the pills more frequently often finish their prescription ahead of schedule. This is due to the regular dose no longer working the same way on the body as they were prescribed to do, because the body is used to taking them. This can result in physical dependence or even addiction even if the user is taking the medication as prescribed.

Doctors prescribe Dilaudid for pain related to cancer and serious injuries, such as burns. The time it takes for Dilaudid to take takes effect varies by how it is taken. When taken orally, Dilaudid typically takes effect within 30 minutes to an hour. When used intranasally, it typically takes 5 minutes, and its effects are almost immediate when taken intravenously. Regardless of the method of administration, the pain-relieving effects of Dilaudid typically last between four and six hours. The drug attaches to receptors in the brain and central nervous system to dull pain. Dilaudid also triggers the release of excessive amounts of dopamine in the brain, causing pleasurable feelings. This activates the reward center of the brain, which interprets the event as something that is important and should be repeated. The more this happens, the less the brain will naturally produce dopamine, and the more reliant the body becomes on Dilaudid.

Though I'd never taken them before I got sober, I was prescribed Vicodin and was given Dilaudid at the hospital and those drugs felt utterly wonderful coursing through my veins. But therein lies the rub; you feel too good when you take them.

Those who abuse Dilaudid recreationally may mix it with alcohol and/or benzodiazepines to get a better high. All three of these drugs are central nervous system depressants. Mixing these drugs amplifies their effects but also dangerously slows breathing and heart rates. Mixing Dilaudid with these drugs can lead to respiratory failure, coma, seizure, or even a fatal overdose. People addicted to Dilaudid often want to relive the euphoric and relaxed feelings they initially experience with the drug, so they continue trying to replicate this "rush." This often leads to abusing harder drugs, like heroin, which are often more accessible.


Hydromorphone (trade names Palladone IR, Palladone SR, Dilaudid and numerous others) is a potent centrally-acting analgesic drug of the opioid class; it is a derivative of morphine, specifically a hydrogenated ketone thereof - therefore a semi-synthetic drug and both an opiate and a true narcotic.

Hydromorphone belongs to a class of drugs called "opioids," which includes morphine. It has an analgesic potency of two to eight times greater than that of morphine and has a rapid onset of action.

It is legally manufactured and distributed in the United States.

hydromorphone is taken to produce feelings of euphoria, relaxation, sedation, and reduced anxiety. It may also cause mental clouding, changes in mood, nervousness, and restlessness. It works centrally (in the brain) to reduce pain and suppress cough.

Hydromorphone use is associated with both physiological and psychological dependence.

Here is an estimated range of times, or detection windows, during which hydromorphone can be detected by various testing methods:

Detection Windows

  • Urine: 3 to 4 days
  • Blood: Up to 24 hours
  • Saliva: Up to 2 days
  • Hair: Up to 90 days

Hydromorphone
Duration:

An opioid that is roughly 5x the potency of IV Morphine. Only comes in IR tablets in the US, and is given mostly as XR in other countries. It is frequently used in hospitals for short, but immediate pain relief during procedures requiring the patient to be awake. Also frequently used as a recreational opiate.

RouteOnsetDurationAfter Effects
Tripsit Factsheets
Intravenous:0-1 minutes1-2 hours1-6 hours
Insufflated:5-10 minutes2-3 hours1-2 hours
Oral:30-60 minutes3-4 hours1-6 hours
Hydromorphone Duration
Avoid:
All other CNS depressants.
Effects:
Euphoria, Dry Mouth, Mood lift, Itchiness, Relaxant, Constipation, Pupil Constriction, Analgesia.

Important Information:

MISUSE OF OPIOID MEDICINE CAN CAUSE ADDICTION, OVERDOSE, OR DEATH. Keep the medication in a place where others cannot get to it.

Taking opioid medicine during pregnancy may cause life-threatening withdrawal symptoms in the newborn.

Fatal side effects can occur if you use opioid medicine with alcohol, or with other drugs that cause drowsiness or slow your breathing.

Do not drink alcohol. Dangerous side effects or death could occur.

Avoid driving or hazardous activity until you know how hydromorphone will affect you. Dizziness or drowsiness can cause falls, accidents, or severe injuries.

Interactions:

Drug Interactions (394) Alcohol/Food Interactions (1) Disease Interactions (17)


What other drugs will affect Hydromorphone?
Opioid medication can interact with many other drugs and cause dangerous side effects or death. Be sure your doctor knows if you also use:
  • other narcotic medications - opioid pain medicine or prescription cough medicine
  • a sedative like:
  • drugs that make you sleepy or slow your breathing - a sleeping pill, muscle relaxer, medicine to treat mood disorders or mental illness
  • drugs that affect serotonin levels in your body - a stimulant, or medicine for depression, Parkinson's disease, migraine headaches, serious infections, or nausea and vomiting
This list is not complete. Other drugs may affect hydromorphone, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here.

A total of 394 drugs are known to interact with Hydromorphone.

  • 116 major drug interactions
  • 277 moderate drug interactions
  • 1 minor drug interactions

Dilaudid (hydromorphone hydrochloride)
Side Effects:
Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
RxList
Opioid medicine can slow or stop your breathing, and death may occur. A person caring for you should seek emergency medical attention if you have slow breathing with long pauses, blue colored lips, or if you are hard to wake up.
Call your doctor at once if you have:
  • noisy breathing, sighing, shallow breathing, breathing that stops during sleep
  • a slow heart rate or weak pulse
  • confusion, feelings of extreme happiness or sadness
  • severe weakness or drowsiness
  • a light-headed feeling, like you might pass out
  • low cortisol levels - nausea, vomiting, loss of appetite, dizziness, worsening tiredness or weakness
Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.
Serious side effects may be more likely in older adults and those who are malnourished or debilitated.
Long-term use of opioid medication may affect fertility (ability to have children) in men or women. It is not known whether opioid effects on fertility are permanent.
Common side effects may include:
  • drowsiness, tiredness
  • dizziness
  • headache
  • constipation, nausea, vomiting, stomach pain
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Dilaudid Injection and HP Injection (hydromorphone hydrochloride)
Maximum Dosage:
Prescribers Digital Reference
Adults:With appropriate dosage titration, there is no maximum dose of hydromorphone.
Geriatric:With appropriate dosage titration, there is no maximum dose of hydromorphone.
Adolescents:With appropriate dosage titration, there is no maximum dose of hydromorphone. The safety and efficacy of extended-release tablets have not been established.
Children:With appropriate dosage titration, there is no maximum dose of hydromorphone. The safety and efficacy of extended-release tablets have not been established.
Infants:With appropriate dosage titration, there is no maximum dose of hydromorphone. The safety and efficacy of extended-release tablets have not been established.
Neonates:Safety and efficacy have not been established.

Dilaudid, Exalgo (hydromorphone) (Rx)
Black Box Warnings:

Opioid analgesic risk evaluation and mitigation strategy (REMS)

  • To ensure that benefits of opioid analgesics outweigh risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a REMS for these products; under requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers
  • Healthcare providers are strongly encouraged to:
    • Complete a REMS-compliant education program
    • Counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products
    • Emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist
    • Consider other tools to improve patient, household, and community safety

Hydromorphone high-potency formulation

  • Hydromorphone high-potency injection is highly concentrated solution of hydromorphone, a potent Schedule II controlled opioid agonist intended for use in opioid-tolerant patients; it is not to be confused with standard parenteral formulations of hydromorphone or other opioids; overdose and death could result
  • Use caution to avoid confusing the highly concentrated (Dilaudid-HP) injection with the less concentrated (Dilaudid) injectable product
  • Schedule II opioid agonists (eg, morphine, oxymorphone, oxycodone, fentanyl, methadone) have highest potential for abuse and risk of producing respiratory depression
  • Alcohol, other opioids, and CNS depressants (eg, sedative-hypnotics) potentiate respiratory depressant effects of hydromorphone, increasing risk of respiratory depression that might result in death
  • Accidental intake may lead to fatal overdose, especially in children High potential for abuse

Risk of medication errors

  • Ensure accuracy when prescribing, dispensing, and administering oral Solution; dosing errors due to confusion between mg and mL can result in accidental overdose and death

Addiction, abuse, and misuse

  • Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death
  • Assess each patient's risk prior to prescribing and monitor all patients regularly for the development of these behaviors or conditions

Life-threatening respiratory depression

  • Serious, life-threatening, or fatal respiratory depression may occur
  • Monitor for respiratory depression, especially during initiation or following a dose increase
  • Instruct patients to swallow tablet/capsule whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose

Accidental exposure

  • Accidental of even 1 dose, especially by children, can result in a fatal overdose

Neonatal opioid withdrawal syndrome

  • Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts
  • Syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight
  • Onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn
  • If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available

Risks from concomitant use with benzodiazepines or other CNS depressants

  • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
  • Reserve concomitant prescribing of oral solution or tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate
  • Limit dosages and durations to the minimum required
  • Follow patients for signs and symptoms of respiratory depression and sedation

Breastfeeding:

Summary of Use During Lactation:
Limited data indicate that hydromorphone is excreted into breastmilk in small amounts, but large maternal dosages have caused neonatal central nervous system depression.

In general, maternal use of oral narcotics during breastfeeding can cause infant drowsiness, central nervous system depression and even death.

Hydromorphone use should be limited in nursing mothers.

Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics. Once the mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of hydromorphone to a few days at a low dosage with close infant monitoring.

If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately.

Drug Levels:

In adults, hydromorphone has an oral bioavailability of 62% and is metabolized to inactive metabolites.

While not commonly used in infants, an appropriate dose for this age group is 10 mcg/kg parenterally or 30 mcg/kg orally every 4 hours as needed.

Effects on Lactation and Breastmilk:

Narcotics can increase serum prolactin.

However, the prolactin level in a mother with established lactation may not affect her ability to breastfeed.

Alternate Drugs to Consider:

IMPORTANT WARNING:
Hydromorphone may be habit forming, especially with prolonged use. Take hydromorphone exactly as directed. Do not take more of it, take it more often, or take it in a different way than directed by your doctor. Hydromorphone may cause serious or life-threatening breathing problems, especially during the first 24 to 72 hours of your treatment and any time your dose is increased. Taking certain medications during your treatment with hydromorphone may increase the risk that you will develop serious or life-threatening breathing problems, sedation, or coma. Do not drink alcohol, take prescription or nonprescription medications that contain alcohol, or use street drugs during your treatment. Swallow the extended-release tablets whole. Do not split, chew, dissolve, or crush them. If you swallow broken, chewed, crushed, or dissolved tablets you may receive too much hydromorphone at once instead of receiving the medication slowly over time. This may cause serious breathing problems or death. Talk to your doctor about the risks of taking hydromorphone.

Liver:
Neither hydromorphone nor oxymorphone have been linked to serum enzyme elevations during therapy or to clinically apparent liver injury.

Hydromorphone Hepatotoxicity:
As with most opiates in current use, therapy with hydromorphone and oxymorphone has not been linked to serum enzyme elevations. There have been no convincing cases of idiosyncratic acute, clinically apparent liver injury attributed to either agent.

FDA PDF Hydromorphone

Mothertobaby PDF Dilaudid

Akorn PDF Dilaudid

Dilaudid is the purest form of synthetic Heroin available thru pharmaceutical companies. Meant strictly for patients prescribed the drug for moderate to severe pain, "D's" are also very common on the streets for having the best intravenous high available of any opiate, yes even better than actual Heroin. (In my opinion.) In pill form 4MG and 8MG rein. No "cut" no 10MG Opiate///325MG Acetametaphine bullshit

Drugs that have similar effects include:
Heroin | Morphine | Hydrocodone | Fentanyl | Oxycodone

Hydromorphone:

Hydromorphone is made from morphine

  • An opioid
  • Used to treat moderate to severe pain.
  • It may be used by mouth or by injection into a vein, muscle, or under the skin
  • Effects generally begin within half an hour and last for up to five hours.
  • Common side effects include dizziness, sleepiness, nausea, itchiness, and constipation.
  • Serious side effects may include abuse, low blood pressure, seizures, respiratory depression, and serotonin syndrome.
  • Hydromorphone 2 mg by mouth is equivalent to approximately 10 mg morphine by mouth.
  • Patented in 1923

Typically, long-term use is only recommended for pain due to cancer.

In 2017, it was the 205th most commonly prescribed medication in the United States, with more than two million prescriptions

  
Bioavailability and Pharmacokinetics of Intranasal Hydromorphone in Patients Experiencing Vasomotor Rhinitis - Background and Objective: Narcotic analgesics such as hydromorphone undergo an extensive ... could alter the rate and extent of absorption of drugs administered by the nasal route.
Friday February 03, 2023 - medscape.com

Investigation leads to seizure of weapons and fentanyl - A search warrant in the Town of Fort Frances has resulted in one individual being arrested and charged with numerous trafficking and weapons offences. On January 31, 2023, at approximately 11:00 a.m., ...
Monday February 06, 2023 - fftimes.com

Woman suing Alberta government over rules around opioid hydromorphone - The province says the risk of these potent opioids getting into the community is too high for it to be administered outside a clinic setting.
Friday February 03, 2023 - globalnews.ca

MySafe defends devices' security after reports some users selling their drugs - Article content “We need to ask ourselves the bigger picture here and acknowledge why and what youth are doing to not die from the toxic drug supply,” MySafe said in a stateme ...
Sunday January 29, 2023 - msn.com

Youth may be buying opioids from B.C. drug vending machines, recovery centre warns - The MySafe machines dispense hydromorphone, a medical-grade opioid, providing people with addiction a lifesaving alternative to the toxic drugs circulating on the street.
Thursday January 26, 2023 - msn.com

Calgary woman sues province to maintain access to drug she says has saved her from overdose - A 21-year-old Calgary woman is suing the Alberta government to maintain access to her prescription for a high-potency opioid, which she says has saved her from overdosing on street drugs.
Thursday February 02, 2023 - cbc.ca

Drug trafficking in Kingston leads to over six-year custodial sentence - Jacques Trudel, 65, convicted of trafficking over two kilograms of methamphetamine in Kingston, has been sentenced to over six years in custody.
Wednesday February 01, 2023 - kingstonist.com

28 drug poisoning deaths in Richmond in 2022 - Twenty-eight people died in Richmond in 2022 of drug poisoning. This is the second highest number since statistics started being made public in 2012 - in 2021, there were 32 drug poisoning deaths in ...
Tuesday January 31, 2023 - richmond-news.com

Man guilty of selling drugs out of truck at Charlotte County gas station - A man was found guilty Tuesday of selling drugs out of his truck in the parking lot of a Charlotte County gas station in 2018. According to the State Attorney’s office, William Leo McBride, 51, was ...
Tuesday January 31, 2023 - winknews.com

Providers, industry associations should do more to address drug theft in assisted living, researchers say - Assisted living and nursing home owners and administrators, as well as long-term care industry associations and others, should increase their efforts to address medication theft and protect residents’ ...
Tuesday January 24, 2023 - mcknightsseniorliving.com

Seven arrests after drug search and seizure in Chatham - Seven people are facing charges after Chatham-Kent police searched a property on Colborne Street in Chatham and found illegal drugs, digital scales, and a large amount of cash.
Wednesday February 01, 2023 - blackburnnews.com

Man, woman charged after 'large' drug bust in the Annex - A man and a woman face a slew of charges after a drug bust in the Annex. Toronto Police say members of the 14 Division Major Crime Unit became involved in a drug investigation on Jan. 9. Investigators ...
Tuesday January 24, 2023 - msn.com

  
Opioids | Link to this page

Home ] [ Controlled Substances ] [ Sources ]


· Controlled Substances
· Opioids
· Hydromorphone